Shelley Wood

(UPDATED) The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable results.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Conference news filled our list this month, dominated by TCT 2024, although two EACTS stories also cracked our top 10.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Critics were quick to point out that this small, short-term trial—mostly in patients with preserved EF—had no medical arm.

A packed program leaves little time for warm beer or Buckingham Palace as the London edition of CVD’s biggest congress kicks off.

This long-awaited RCT, seen by some as a COAPT/MITRA-FR tiebreaker, will be unveiled at ESC 2024—with key design tweaks.

A study tracking CV risks with a low-cal sweetener topped a diverse list of stories spanning meeting updates and sex advice.

The AHA was founded by physicians committed to the outlandish notion that a CVD diagnosis was not a death sentence.

Interventional news dominated this month, but a few stories on heart failure and cardiometabolic disease also made the list.